| Document |
Document Title |
|
WO/2024/067709A1 |
Provided are a compound (I) or a pharmaceutically acceptable salt thereof, an ester thereof, an optical isomer thereof, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, an N-oxide thereof, an isotopical...
|
|
WO/2024/031993A1 |
The present invention provides a star-shaped molecule capable of being used for a hole transport layer, a preparation method therefor, and use thereof. The star-shaped molecule capable of being used for the hole transport layer has a str...
|
|
WO/2024/033479A1 |
The application relates to compounds of formula (B1A), (B1B), (B1C) or a salt, a solvate, a hydrate, a polymorph, a tautomer, a racemate or a stereoisomer thereof, to pharmaceutical compositions comprising such a compound, and to the com...
|
|
WO/2024/008766A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (...
|
|
WO/2024/008805A1 |
The invention relates to heteroaromatic ketones of formula (I) for radical and cationic polymerization (I), wherein the substituents A, B, C and D can be the same or different and are nitrogen or carbon, while R1 and R2, independently of...
|
|
WO/2023/220572A1 |
The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and/or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I). Further disclo...
|
|
WO/2023/215220A1 |
The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
|
|
WO/2023/201019A1 |
Improved methods for synthesizing taurolidine, improved compositions or formulations comprising taurolidine and methods for reducing an amount of impurities in taurolidine are provided herein, among other things. The taurolidine may be s...
|
|
WO/2023/200964A1 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
WO/2023/196727A1 |
The present disclosure relates generally to Retinoblastoma (Rb1) protein targeting 1, 2, 4-thiadiazolidin-3, 5-dione compounds, wherein the Rb1 protein is a known tumor suppressor protein, and methods of use thereof. In some aspects, the...
|
|
WO/2023/177146A1 |
The present disclosure relates to: a novel thiadiazole derivative compound; and a pharmaceutical composition for preventing or treating inflammatory diseases, the composition including the novel thiadiazole derivative compound as an acti...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/165957A1 |
The present invention relates to substituted 1,2,4-thiadiazolyl picolinamide of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their ...
|
|
WO/2023/165958A1 |
Substituted 1,2,4-thiadiazolyl isonicotinamide, salts thereof and their use as herbicidally active substances The present invention relates to substituted 1,2,4-thiadiazolyl isonicotinamide of the general formula (I) or salts thereof, wh...
|
|
WO/2023/164179A1 |
The present disclosure provides, in part, benzothia(dia) zepine compounds of formula II and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
|
|
WO/2023/164183A1 |
The present disclosure provides, in part, benzothia(dia)zepine compounds, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
|
|
WO/2023/161490A1 |
The present invention relates to a process for manufacturing high purity hydrochlorothiazide. In particular the present invention relates to a process for reducing amount of 6-chloro-4- nitroso-3,4-dihydro-2H-1, 2, 4-benzothiadiazide-7-s...
|
|
WO/2023/164186A1 |
The present disclosure provides, in part, benzothia(dia)zepine compounds of formula II, and pharmaceutical compositions thereof, and methods of treating Hepatitis B (HBV) and Hepatitis D (HDV) infections.
|
|
WO/2023/150523A1 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
WO/2023/150535A1 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
WO/2023/150150A1 |
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
|
|
WO/2023/147531A1 |
Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosph...
|
|
WO/2023/018472A9 |
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
|
|
WO/2023/131951A1 |
Novel non-coded amino acids derivatives having herbicidal activity, agricultural compositions, process for their manufacture and their use in crop protection are provided.
|
|
WO/2023/111996A1 |
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one ...
|
|
WO/2023/091524A1 |
The present disclosure provides methods of treating catecholaminergic polymorphic ventricular tachycardia, comprising administering a pharmaceutical composition comprising, in a unit dosage form, a therapeutically-effective amount of 4-[...
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/064152A1 |
Compounds of formula I, that modulate DCAF15 and induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity ...
|
|
WO/2023/060573A1 |
Poly theta inhibitor (I), X is -N-or -C-; ring A is phenyl or a five to ten membered heteroaryl ring containing, inclusive of X, one to four heteroatoms independently selected from nitrogen, oxygen, or sulfur, Ar1 is phenyl, heteroaryl, ...
|
|
WO/2023/061415A1 |
The disclosure relates to thiadiazolyl derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
|
|
WO/2023/061051A1 |
Disclosed in the present application are a class of compounds containing a thiazole or thiadiazole structure and the use thereof, which belong to the technical field of medicine. According to the present application, the structure of a l...
|
|
WO/2023/045910A1 |
The present application discloses a small-molecule compound having a naphthol ether structure, and a use thereof. Disclosed in the present application are a compound having a structure represented by general formula (I), a pharmaceutical...
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/031609A1 |
The invention relates to a compound of formula I, (I) wherein: R1, R2, R3 and R4 are as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, which compounds are useful in the treatment of a disorder or ...
|
|
WO/2023/011312A1 |
The present application belongs to the field of medicine, and discloses a multi-substituted thiazole derivative and an application thereof in disease treatment. Specifically, disclosed are a compound represented by formula I or a pharmac...
|
|
WO/2023/278604A1 |
Methods for treating ophthalmic diseases and disorders such as treating presbyopia or cataract in a subject in need thereof. The methods require administering to the subject an effective amount of a composition comprising a compound that...
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2022/253645A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2022/253997A1 |
The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter(ASBT) and/or liver bile acid transport (L...
|
|
WO/2022/211520A1 |
The present invention relates to a novel compound and a use thereof for treatment of autoimmune disease. A pharmaceutical composition for treatment or prevention of autoimmune disease, comprising the novel compound of the present inventi...
|
|
WO/2022/203074A1 |
Provided is a non-aqueous electrolyte containing a non-aqueous electrosolvent and a lithium salt, wherein the non-aqueous solvent includes a carbonate solvent, the lithium salt contains a fluorine-containing cyclic sulfonylimide salt rep...
|
|
WO/2022/204288A1 |
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. ...
|
|
WO/2022/194841A1 |
Substituted 1,2,4-thiadiazoles,salts thereof and their use as herbicidally active substances The present invention relates to substituted 1,2,4-thiadiazoles of the general formula (I) or salts thereof, where the radicals in the general f...
|
|
WO/2022/194842A1 |
Substituted 1,2,4-thiadiazoles, salts thereof and their use as herbicidally active substances The present invention relates to substituted 1,2,4-thiadiazoles of the general formula (I) or salts thereof, where the radicals in the general ...
|
|
WO/2022/194843A1 |
Substituted 1,2,4-thiadiazoles, salts thereof and their use as herbicidally active substances The present invention relates to substituted 1,2,4-thiadiazoles of the general formula (I) or salts thereof, where the radicals in the general ...
|
|
WO/2022/182699A1 |
The present disclosure encompasses solid state forms of Tideglusib, in embodiments crystalline polymorphs or salts or co-crystals of Tideglusib, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/170437A1 |
The present invention provides methods of treating or alleviating a symptom of arrhythmogenic cardiomyopathy (ACM) by administration of a thiadiazolidindione or a derivative thereof such as tideglusib or NPE1000928. Symptoms of ACM ameli...
|
|
WO/2022/166680A1 |
Provided are a novel crystal form of Odevixibat (referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing said crystal form, and a use of said crystal form in the preparation of a IBAT inhibito...
|
|
WO/2022/092260A1 |
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...
|
